Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;3(3):261-77.
doi: 10.4155/ppa.14.18.

Recent advances in antimultiple myeloma drug development

Nuozhou Wang  1 , Patrick Bartlow, Qin Ouyang, Xiang-Qun Xie
Affiliations
Review

Recent advances in antimultiple myeloma drug development

Nuozhou Wang et al. Pharm Pat Anal. 2014 May.

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the aberrant proliferation of terminally differentiated plasma B cells with impairment in apoptosis capacity. Particularly, osteolytic bone diseases and renal failure resulting from hyperparaproteinemia and hypercalcemia have been the major serious sequelae that are inextricably linked with MM tumor progression. Despite the introduction of new treatment regimens, problematic neuropathy, thrombocytopenia, drug resistance and high MM relapse rates continue to plague the current therapies. New chemical agents are in development on the basis of understanding several signaling pathways and molecular mechanisms like tumor necrosis factor-α, proteasome, PI3K and MARKs. This review focuses on the most recent patents and clinical trials in the development of new medicine for the treatment of multiple myeloma. Furthermore, the important signaling pathways involved in the proliferation, survival and apoptosis of myeloma cells will be discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Frequency of patents and literature citations related to ‘multiple myeloma’ from 2005 to 2013.
Figure 2
Figure 2. The published patents related to multiple myeloma treatments and their associated targets
APRIL: A proliferation-inducing ligand; BMSC: Bone marrow stromal cells; CB2: Cannabinoid receptor 2; CD40: TNF receptor superfamily member 5; CXCR4: Chemokine receptor type 4; DKK1: Dickkopf-related protein 1; ERK: Extracellular signal-regulated kinases; FGFR3: Fibroblast growth factor receptor 3; HGF: Hepatocyte growth factor; Hsp90: Heat shock protein 90; JAK: Janus kinase; MAPK: Mitogen-activated protein kinase; MEK: Mitogen-activated protein kinase kinase; MIP-1α: Macrophage inflammatory protein-1α; MM cell: Multiple myeloma cell; mTOR: Mammalian target of rapamycin; PI3K: Phosphatidylinositide 3-kinases; PPARγ: Peroxisome proliferator-activated receptor gamma; PTEN: Phosphatase and tensin homolog; SDF-1α: Stromal cell-derived factor 1; STAT3: Signal transducer and activator of transcription 3; UPR: Unfolded protein response; VCAM: Vascular cell adhesion protein 1; VLA4: Very late antigen-4.
See this image and copyright information in PMC

References

    1. Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int. J. Hematol. 2011;94(4):334–343. - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012;62(1):10–29. - PubMed
    1. Dimopoulos MA, Terpos E. Multiple myeloma. Ann. Oncol. 2010;21(Suppl. 7):vii143–vii150. - PubMed
    1. Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J. Clin. Oncol. 2010;28(9):1599–1605. - PubMed
    1. Nolan KD, Mone MC, Nelson EW. Plasma cell neoplasms. Review of disease progression and report of a new variant. Surg. Oncol. 2005;14(2):85–90. - PubMed

Publication types

Substances

LinkOut - more resources